# A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

> **NCT02541383** · PHASE3 · COMPLETED · sponsor: **Intergroupe Francophone du Myelome** · enrollment: 1085 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
- **DRUG:** Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT02541383
- **Lead sponsor:** Intergroupe Francophone du Myelome
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2020-08-27
- **Final completion:** 2023-09-01
- **Target enrollment:** 1085 (ACTUAL)
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02541383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02541383, "A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02541383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*